Krystal Biotech reports Q4 net product revenue of $42.1M from VYJUVEK; net income of $8.7M

Krystal Biotech, Inc.

2023-FY EPS reported $0.39 revenue$50,699,000

Net product revenue $42.1M in Q4 2023; $50.7M full year 2023; gross margin 93% in Q4.
FDA aligned on single-arm study to approve B-VEC eyedrops for ocular DEB in ~10 patients; study starts 2H 2024.
Cash & investments $594.1M at year-end; net income $8.7M in Q4 vs net loss of $32.1M in prior-year quarter.
First patient dosed in Phase 1 KB408 for AATD; FDA granted ODD. Interim data expected 2H 2024.
FY2024 non-GAAP R&D+SG&A guidance $150M-$175M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Krystal Biotech, Inc. reported the quarter and year ended December 31, 2023 results: revenue $42.1M in 4Q and $50.7M for the year.

Period: the quarter and year ended December 31, 2023
Revenue: $42.1M in 4Q and $50.7M for the year
Result: reported results

Exact text from the filing

in such filing. --- EX-99.1 (EX-99.1) --- Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates • Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of the use of B-VEC eyedrop formulation • Reached alignment with FDA to enable approval of B-VEC

View on SEC.gov

Browse all earnings releases →

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-24-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.